$21.05 -0.09 (-0.43%)
2/10/2012 4:00 PM

Pfizer, Inc. (NYSE:PFE)

CAPS Rating: 4 out of 5

A research-based pharmaceutical company, Pfizer discovers, develops, manufactures, and markets prescription medicines such as Lipitor, Celebrex, and Viagra.

Results 1 - 20 of 991 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar Beau1700 (31.53) Submitted: 2/7/2012 4:52:57 PM : Outperform Start Price: $20.99 PFE Score: +0.67

deep pockets

Recs

0
Member Avatar rurbey (< 20) Submitted: 1/17/2012 8:27:23 PM : Outperform Start Price: $21.03 PFE Score: -2.58

good pipeline, well managed, safe dividend, aging population

Recs

0
Member Avatar Mainepilot (< 20) Submitted: 1/6/2012 11:15:57 AM : Outperform Start Price: $21.48 PFE Score: -7.01

Dividends and covered call options.

Recs

0
Member Avatar Staka (98.56) Submitted: 12/31/2011 3:23:41 PM : Outperform Start Price: $21.27 PFE Score: -7.65

Positive:
- Defensive Business
- Slightly expensive but with a good dividend
- 22 drugs in phase III, a total of 95 in the pipeline

Negative:
- Many hidden risks (law suits, FDA)
- Hugh revenue loss at the end of 2012, but this is a well known fact which should be priced in
- Chart somewhat overextended

Category: MT+

Recs

0
Member Avatar dulcie99 (42.34) Submitted: 12/19/2011 9:06:31 PM : Outperform Start Price: $21.09 PFE Score: -10.17

outperform

Recs

1
Member Avatar thstorm93 (60.15) Submitted: 12/8/2011 12:42:29 AM : Outperform Start Price: $18.24 PFE Score: +3.66

Expiring patents are already priced in so that will have no effect on their stock price. They have a history of creating blockbuster drugs and there are more to come as they currently have 118 drugs in the pipeline. 60 of those are in phase 2 or 3. Last year they surpassed $1 billion in annual revenue in both China and Brazil for the first time in the company’s history. These are two of the largest emerging pharmaceutical markets globally so continued growth is expected. This is a dependable, low risk company, with growth potential and a great dividend. OUTPERFORM!!!

Recs

0
Member Avatar tbonci (66.48) Submitted: 11/26/2011 12:02:09 PM : Outperform Start Price: $18.62 PFE Score: +0.67

Huge pharma company with over a dozen household name brands, who have managed to grow operating margins. A health care giant who is well positioned to support the growing/aging population.

Recs

0
Member Avatar stockstar69 (23.72) Submitted: 11/21/2011 2:06:52 PM : Outperform Start Price: $18.83 PFE Score: -0.86

Still a good dividend, good research pipeline and lots of cash.

Recs

0
Member Avatar TMFDitty (99.48) Submitted: 11/15/2011 11:21:50 AM : Outperform Start Price: $19.61 PFE Score: -0.15

8x FCF seems a fair price to pay for 4% growth and a 4% divvy. I'll take that offer.

Recs

0
Member Avatar BinyaminK (21.70) Submitted: 11/9/2011 1:47:16 PM : Outperform Start Price: $19.26 PFE Score: +1.04

This is a "Giant Tortoise Stock." Like a giant tortoise, It may be big and slow, but it has a hard shell (economic moat), can swim far (enter into new and emerging markets and industries), and live long.

Recs

0
Member Avatar gtnuno (41.55) Submitted: 11/7/2011 10:28:56 AM : Underperform Start Price: $19.31 PFE Score: -1.59

Expiring patents

Recs

0
Member Avatar hurricanehedge (47.20) Submitted: 11/7/2011 10:16:20 AM : Outperform Start Price: $19.37 PFE Score: +1.53

Let all their other drugs disappear are consumers ever going to stop using Advil and robitussin? The answer is no.

Recs

0
Member Avatar ryatin (< 20) Submitted: 10/28/2011 12:17:23 PM : Outperform Start Price: $19.37 PFE Score: +3.87

Patents for several household name drugs expire before end of 2013 with no large market drugs in pipeline until 2015 and those still await FDA approval. Short-term gain likely with a possible long term gain, but mid-range a virtually loss assured.

Recs

0
Member Avatar RenoNV (53.82) Submitted: 10/17/2011 1:10:12 AM : Outperform Start Price: $18.58 PFE Score: +2.33

Undervalued with good dividend.

Recs

0
Member Avatar mikemariani (66.44) Submitted: 9/30/2011 10:39:44 AM : Outperform Start Price: $17.48 PFE Score: +3.03

magic formula

Recs

0
Member Avatar Palido (53.52) Submitted: 9/27/2011 4:09:59 PM : Outperform Start Price: $17.40 PFE Score: +6.87

Decent dividend, fairly priced.

Recs

0
Member Avatar Tony007x (53.64) Submitted: 9/24/2011 3:39:51 AM : Underperform Start Price: $17.05 PFE Score: -6.22

expecting PFE to fall couple of weeks before rebounding

Recs

0
Member Avatar Danpines (43.74) Submitted: 9/18/2011 8:40:24 AM : Outperform Start Price: $17.43 PFE Score: +13.13

Great undervalued company. They have items comming off patent which is priced in the stock share.

Recs

0
Member Avatar mrpeila73 (< 20) Submitted: 8/31/2011 1:16:22 AM : Outperform Start Price: $18.60 PFE Score: +3.46

Limitless?

Recs

0
Member Avatar The1ntervention (< 20) Submitted: 8/18/2011 12:15:12 PM : Outperform Start Price: $17.58 PFE Score: +3.19

The new JAK rheumatoid drugs look promising and a lot of people would love to have an oral medication that can be used with or after failure of MTX.

Featured Broker Partners


Advertisement